Moreover, AMD3100 is receiving interest as an anti-cancer agent that disrupts the CXCR4/CXCL12 chemokine receptor interaction between neoplastic cells and their microenvironment in tumor progression and metastasis. Here, CXCR4 is linked to neoplasm.